Every year, more than 10 million people worldwide fall ill with cancer for the first time. According to the most recent information, there are approximately 420,000 new cases of cancer in Germany. According to estimates of the World Health Organization, 15.7 million people will fall newly ill with cancer in the year 2020. This would mean that the rate of new cases would increase by 50 percent in the next 15 years. The reason for this is the steadily aging population which becomes increasingly susceptible to cancer with advancing age.

Pharmaceutical and medical technology companies invest hundreds of billions annually into new and innovative therapeutic approaches to improve cancer treatments and help affected persons to survive for longer periods. Nevertheless, cancer remains the second most frequent cause of death after heart disease. Every year, approximately 6.7 million patients worldwide die from the consequences of cancer.

Nano-Cancer^® therapy – the fourth pillar

After the presence of a tumor is determined, one of the three standard treatments is generally applied, either alone or in combination: Surgery, radiotherapy and/or chemotherapy. The last two types of therapy in particular are accompanied by severe side effects which greatly impact the patient’s quality of life.

MagForce’s vision is to establish Nano-Cancer^® therapy as the fourth pillar in addition to today’s three common standard treatments. In less than ten years, Nano-Cancer^® therapy is intended to reach the same position as radiation therapy, but without the radiation load for the patient. Multiresistant tumors will therefore no longer lead to certain death.

Due to the good tolerability and the ability to repeat it as often as desired, Nano-Cancer^® therapy will be used as an adjuvant to most combination therapies in the future. The acceptance rate of Nano-Cancer^® therapy by patients is already very high. Therapy is minimally invasive, makes outpatient treatment possible, and the patients’ quality of life is not negatively affected.